文献速递肾移植水电解质与酸碱

肾移植受者血磷与心血管疾病、全因死亡或移植物失功风险:FAVORIT试验辅助研究

Serum Phosphorus and Risk of Cardiovascular Disease, All-Cause Mortality, or Graft Failure in Kidney Transplant Recipients: An Ancillary Study of the FAVORIT Trial Cohort.
PubMed 文献 · Am J Kidney Dis · 2017-06-02

该研究基于FAVORIT试验3138例肾移植受者,中位随访4.0年,发现血磷每升高1 mg/dL与心血管疾病风险无显著关联,但与移植物失功和全因死亡风险增加独立相关。校正肾脏指标后关联减弱,提示血磷可能部分通过肾功能介导。

要点

  • 血磷每升高1 mg/dL与移植物失功风险增加36%相关。
  • 血磷每升高1 mg/dL与全因死亡风险增加21%相关。
  • 血磷与心血管疾病风险无显著独立关联。

核心结论

  • 在长期肾移植受者中,血磷水平与心血管疾病风险仅呈边缘关联,与移植物失功和全因死亡关联更强。

研究设计与样本

  • FAVORIT试验辅助队列研究,纳入3138例稳定肾移植受者,随机分组时测定血磷,中位随访4.0年。

主要发现

  • 随访期间发生436例心血管疾病事件、238例移植物失功和348例死亡。
  • 校正多因素后,血磷每升高1 mg/dL与心血管疾病风险无显著关联(HR 1.06,95%CI 0.92-1.22)。
  • 校正多因素后,血磷每升高1 mg/dL与移植物失功风险增加相关(HR 1.36,95%CI 1.15-1.62)。
  • 校正多因素后,血磷每升高1 mg/dL与全因死亡风险增加相关(HR 1.21,95%CI 1.04-1.40)。
  • 不校正肾脏指标时,关联增强:心血管疾病HR 1.14(95%CI 1.00-1.31),移植物失功HR 1.72(95%CI 1.46-2.01),死亡HR 1.34(95%CI 1.15-1.54)。

临床怎么用

  • 对稳定肾移植受者,监测血磷可能有助于识别移植物失功和死亡高风险个体。
  • 血磷与硬终点关联的因果性需随机对照试验评估降磷治疗的影响。

局限性

  • 缺乏甲状旁腺激素、成纤维细胞生长因子23或维生素D代谢物浓度数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mild hyperphosphatemia is a putative risk factor for cardiovascular disease [CVD], loss of kidney function, and mortality. Very limited data are available from sizable multicenter kidney transplant recipient (KTR) cohorts assessing the potential relationships between serum phosphorus levels and the development of CVD outcomes, transplant failure, or all-cause mortality. STUDY DESIGN: Cohort study. SETTING & PARTICIPANTS: The Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial, a large, multicenter, multiethnic, controlled clinical trial that provided definitive evidence that high-dose vitamin B-based lowering of plasma homocysteine levels did not reduce CVD events, transplant failure, or total mortality in stable KTRs. PREDICTOR: Serum phosphorus levels were determined in 3,138 FAVORIT trial participants at randomization. RESULTS: During a median follow-up of 4.0 years, the cohort had 436 CVD events, 238 transplant failures, and 348 deaths. Proportional hazards modeling revealed that each 1-mg/dL higher serum phosphorus level was not associated with a significant increase in CVD risk (HR, 1.06; 95% CI, 0.92-1.22), but increased transplant failure (HR, 1.36; 95% CI, 1.15-1.62) and total mortality risk associations (HR, 1.21; 95% CI, 1.04-1.40) when adjusted for treatment allocation, traditional CVD risk factors, kidney measures, type of kidney transplant, transplant vintage, and use of calcineurin inhibitors, steroids, or lipid-lowering drugs. These associations were strengthened in models without kidney measures: CVD (HR, 1.14; 95% CI, 1.00-1.31), transplant failure (HR, 1.72; 95% CI, 1.46-2.01), and mortality (HR, 1.34; 95% CI, 1.15-1.54). LIMITATIONS: We lacked data for concentrations of parathyroid hormone, fibroblast growth factor 23, or vitamin D metabolites. CONCLUSIONS: Serum phosphorus level is marginally associated with CVD and more strongly associated with transplant failure and total mortality in long-term KTRs. A randomized controlled clinical trial in KTRs that assesses the potential impact of phosphorus-lowering therapy on these hard outcomes may be warranted.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Merhi B, Shireman T, Carpenter MA, et al. Serum Phosphorus and Risk of Cardiovascular Disease, All-Cause Mortality, or Graft Failure in Kidney Transplant Recipients: An Ancillary Study of the FAVORIT Trial Cohort. Am J Kidney Dis. 2017. PMID: 28579423. doi:10.1053/j.ajkd.2017.04.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。